3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Glioblastoma
7
Recurrence
2
Prostatic Neoplasms
2
Brain Neoplasms
2
Astrocytoma
2
Optic Nerve Glioma
1
Oligodendroglioma
1
Metatropic dwarfism
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Leukemia, Eosinophilic, Acute
1
Leukemia, Basophilic, Acute
1
Gliosarcoma
1
Glioma
1
Diffuse Intrinsic Pontine Glioma
1
Congenital Abnormalities
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Vinorelbine
1
Gemcitabine
1
Drug Therapy
1
Cisplatin
1
Cilengitide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Metatropic dwarfism
×
Cilengitide
×
Clear all
NCT00842712
2017-01-13
CERTO
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
232 enrolled
17 charts